GNPXbenzinga

Genprex Announced It Has Entered Into An Exclusive Patent License Agreement With Uthealth Houston Granting Genprex Exclusivity And Commercial Rights Relating To Its Lead Drug Candidate, Reqorsa Gene Therapy (Quaratusugene Ozeplasmid) For The Potential Tre

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 6, 2025 by benzinga

    Genprex Announced It Has Entered Into An Exclusive Patent License Agreement With Uthealth Houston Granting Genprex Exclusivity And Commercial Rights Relating To Its Lead Drug Candidate, Reqorsa Gene Therapy (Quaratusugene Ozeplasmid) For The Potential Tre | GNPX Stock News | Candlesense